Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To evaluate the influence of carvedilol (Talliton, Egis, Hungary) on daily profile of blood pressure (BP), anatomical and functional conditions of left ventricle (LV) and cerebral circulation in patients with arterial hypertension (AH), stage II-III. Material and methods. 30 patients (10 men, 20 women, average age 51,9±7,9 y.o.) with AH II-III stage ( RSSC,2004) and with initially affected daily profile of BP, cerebral circulation, anatomical and functional disorders of LV took carvedilol 25-75 mg/d during 6 months. Hemodynamics was estimated by ambulatory BP monitoring, Doppler Echocardiography, and ultrasound Dopplerography of extra cranial vessels. Results. A normalizing effect of carvedilol on abnormal daily profile of BP and cerebral circulation was determined. The treatment resulted in the regress of LV hypertrophy with predominant reduction of interventricular septum thickness and also the transformation of concentrical LV hypertrophy in excentrical one. Conclusion. Long-term therapy with carvedilol in patients with AH II-III stage provides a stable BP control and cardioprotective effect, improves cerebral circulation.

About the Authors

L. I. Markova
Moscow State University of Medicine and Stomatology
Russian Federation
Chair of therapy№1, Faculty of postgraduate education

A. I. Radzevich
Moscow State University of Medicine and Stomatology
Russian Federation
Chair of therapy№1, Faculty of postgraduate education


1. Лазебник Л.Б., Комиссаренко И.А. Применение β-блокаторов в лечении артериальной гипертонии у больных старших возрастных групп на фоне ишемической болезни сердца. Кардиология 2004; 4: 106-112.

2. Лелюк В.Г., Лелюк С.Э. Ультразвуковая ангиопатия. Реальное время, М. 1999: 189.

3. Праскурничий Е.А., Шевченко О.П., Макарова С.В. Влияние карведилола на выраженность гипертензивной реакции в условиях стресс-тестирования у больных артериальной гипертензией. Кардиоваск Тер и Проф 2004; 5(3): 10-17.

4. Преображенский Д.В., Сидоренко Б.А., Алёхин М.Н. и соавт. Гипертрофия левого желудочка при гипертонической болезни. Часть II. Прогностическое значение гипертрофии левого желудочка. Кардиология 2003; 11: 98-101.

5. Суслина З.А., Гераскина Л.А., Фонякин А.В. Актуальные вопросы и рациональный подход к лечению артериальной гипертонии при сосудистой патологии мозга. Кардиоваск Тер и Проф 2005; 3(4, часть I): 82-87.

6. Чихладзе Н.М., Чазова И.Е. Возможности применения бета-адреноблокаторов с вазодилaтирующими свойствами у больных артериальной гипертонией. Consilium Medicum 2004; 2: 39-41.

7. Carlson W, Oberg K. Clinical pharmacology of carvedilol. J Cardiovasc Pharmacol Ther. 1999; 4: 205-218.

8. Devereux R.B. Therapeutic options in minimizing LVH. Am Heart J. 2000; 139: 9-14.

9. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997; 54: 161-185.

10. Gehr TWB, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol. 1999; 55: 269-77.

11. Macfarlane PW, Murray GD, McGowan J, et al. Analysis of 24 hour ambulatory ECGs from the CHRISTMAS study (abstract no. 3026). Circulation 2002; 106 (suppl. 19): 613-620.

For citation:

Markova L.I., Radzevich A.I. HEMODYNAMIC EFFECTS OF CARVEDILOL IN PATIENTS WITH ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2006;2(3):12-18. (In Russ.)

Views: 366

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)